Blockade of Fatty Acid Synthase Induces Ubiquitination and Degradation of Phosphoinositide-3-Kinase Signaling Proteins in Ovarian Cancer

Aberrations within the phosphoinositide-3-kinase (PI3K) pathway occur in greater than 45% of ovarian carcinomas. The PI3K cascade transmits signals from ErbB receptors downstream to S6 and 4EBP1, which are involved in protein biosynthesis. Many ovarian carcinomas reveal hyperactivation of ErbB1 (epidermal growth factor receptor) or ErbB2 (HER2/neu). Unfortunately, the benefit of anti-ErbB drugs is yet rather limited in ovarian carcinomas. Thus, novel targeting strategies are needed for ovarian carcinomas. The lipogenic enzyme fatty acid synthase (FASN) is overexpressed in approximately 80% of ovarian carcinomas. It stimulates cell growth and signifies poor prognosis. FASN inhibition impedes (ErbB) membrane receptor signaling and sensitizes cells against anti-ErbB drugs. Here, we show that the FASN inhibitor C75 and FASN-targeting siRNAs abrogate growth, induce apoptosis, and downregulate phosphorylation/expression of the PI3K effectors AKT, mTOR, p70S6K, S6, and 4EBP1. In contrast, FASN inhibition impairs expression but only weakly affects phosphorylation of ERK1/2 mitogen-activated protein kinases in ovarian carcinoma cells. Cycloheximide-mediated blockade of protein translation reveals that C75- or FASN siRNA–induced shutdown of FASN accelerates decomposition of signaling proteins. This effect is caused by C75- or FASN siRNA–dependent stimulation of ubiquitination followed by lysosomal-autophagosomal proteolysis. In contrast, PI3K inhibitor LY294002 blocks phosphorylation but does not reduce expression/stability of PI3K effectors. Forced expression of hyperactive (HA) AKT1, unlike HA-MEK1, impairs the growth-inhibitory action of C75. We provide first evidence that the anticancer action of FASN inhibitors is at least partially mediated by drug-dependent proteolysis of PI3K effectors. FASN is a promising cancer target, whose inhibition not only abrogates lipogenesis, which is indispensable for cancer growth, but also downregulates oncogenic PI3K signaling. Mol Cancer Res; 9(12); 1767–79. ©2011 AACR.

[1]  Jeffrey W. Smith,et al.  Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer , 2007, BMC Genomics.

[2]  P. Houghton,et al.  mTOR and cancer therapy , 2006, Oncogene.

[3]  M. Krainer,et al.  Targeting signaling pathways in ovarian cancer , 2008, Expert opinion on therapeutic targets.

[4]  E. Henske,et al.  Rheb Inhibits C-Raf Activity and B-Raf/C-Raf Heterodimerization* , 2006, Journal of Biological Chemistry.

[5]  H. Hollema,et al.  The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer , 2008, British Journal of Cancer.

[6]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[7]  Jorma Isola,et al.  Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma , 2006, Journal of Molecular Medicine.

[8]  J. Testa,et al.  Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells , 2005, Oncogene.

[9]  W. Berger,et al.  Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. , 2009, Biochemical and biophysical research communications.

[10]  R. Dai,et al.  Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells. , 2009, International journal of oncology.

[11]  J. Blenis,et al.  Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. , 2002, Molecular cell.

[12]  G. Pasternack,et al.  Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. , 1996, Cancer research.

[13]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[14]  I. Gout,et al.  The ubiquitination of ribosomal S6 kinases is independent from the mitogen-induced phosphorylation/activation of the kinase. , 2009, The international journal of biochemistry & cell biology.

[15]  A. Jakobsen,et al.  Prognostic significance of p53, Her‐2, and EGFR overexpression in borderline and epithelial ovarian cancer , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[16]  C. Townsend,et al.  Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. , 2000, Science.

[17]  J. Gustafsson,et al.  ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. , 2004, Gynecologic oncology.

[18]  T. Gansler,et al.  Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. , 1997, Human pathology.

[19]  P. Visca,et al.  Immunohistochemical study of fatty acid synthase in ovarian neoplasms. , 2000, Oncology reports.

[20]  J. Graff,et al.  Targeting the eukaryotic translation initiation factor 4E for cancer therapy. , 2008, Cancer research.

[21]  Xin Huang,et al.  Somatic mutation and gain of copy number of PIK3CA in human breast cancer , 2005, Breast Cancer Research.

[22]  M. Loda,et al.  Fatty acid synthase as a potential therapeutic target in cancer. , 2010, Future oncology.

[23]  T. Fenton,et al.  Regulation of ribosomal protein S6 kinases by ubiquitination. , 2008, Biochemical and biophysical research communications.

[24]  W. Berger,et al.  The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells , 2011, Breast Cancer Research and Treatment.

[25]  Deanna R. Brickley,et al.  Ubiquitin Modification of Serum and Glucocorticoid-induced Protein Kinase-1 (SGK-1)* , 2002, The Journal of Biological Chemistry.

[26]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[27]  A. Bogusz,et al.  A novel N‐terminal hydrophobic motif mediates constitutive degradation of serum‐ and glucocorticoid‐induced kinase‐1 by the ubiquitin–proteasome pathway , 2006, The FEBS journal.

[28]  Xianglin Shi,et al.  G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. , 2004, American journal of physiology. Cell physiology.

[29]  G. Ronnett,et al.  C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Adams,et al.  Development of the Proteasome Inhibitor Velcade™ (Bortezomib) , 2004, Cancer investigation.

[31]  A. Gaiger,et al.  Upregulation of retinoic acid receptor‐β by the epidermal growth factor‐receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways , 2007, Journal of cellular physiology.

[32]  H. Aguilar,et al.  Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity , 2009, Clinical Cancer Research.

[33]  S. Kridel,et al.  Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. , 2007, Cancer research.

[34]  Ken Saito,et al.  Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. , 2006, Cancer research.

[35]  V. Hill,et al.  Monitoring autophagy in lysosomal storage disorders. , 2009, Methods in enzymology.

[36]  M. Pagano,et al.  Activation of Protein Kinase C Triggers Its Ubiquitination and Degradation , 1998, Molecular and Cellular Biology.

[37]  P. Gómez-Puertas,et al.  Novel effect of C75 on carnitine palmitoyltransferase I activity and palmitate oxidation. , 2006, Biochemistry.